Trial Profile
A study to evaluate whether the alemtuzumab induction significantly reduced acute rejection rate in simultaneous pancreas kidney transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin
- Indications Kidney-pancreas transplant rejection
- Focus Therapeutic Use
- 29 Dec 2015 New trial record